ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway

ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway

Abstract Background ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the expression and role of ER-α36 in cis...

Full description

Bibliographic Details
Main Authors: Linlin Zhu, Jiao Zou, Yuanyin Zhao, Xiaomei Jiang, Yang Wang, Xiangwei Wang, Bin Chen
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
ER-α36
Cisplatin resistance
Breast cancer
EGFR
HER-2
Online Access:http://link.springer.com/article/10.1186/s13046-018-0798-z

Internet

http://link.springer.com/article/10.1186/s13046-018-0798-z

Similar Items